INTRODUCTION: Bortezomib-induced peripheral neuropathy typically presents as a painful, length-dependent sensory predominant neuropathy. METHODS: A case report, including nerve pathology, is presented of a man with multiple myeloma who developed a severe motor predominant polyradiculoneuropathy in the setting of bortezomib treatment. We also review the Mayo Clinic Hematology Dysproteinemia database for patients treated with bortezomib. RESULTS: A 53-year-old man with Stage III multiple myeloma developed a severe motor predominant polyradiculoneuropathy following bortezomib treatment with electrophysiological features of multiple conduction blocks and pathological evidence of peripheral nerve microvasculitis. Our institutional experience is that 36.5% of dysproteinemia patients treated with bortezomib develop treatment-emergent peripheral neuropathy, and the most common pattern is a painful sensory predominant peripheral neuropathy. CONCLUSIONS: A motor predominant polyradiculoneuropathy is a rare presentation of bortezomib-associated peripheral neuropathy in multiple myeloma patients which may progress despite treatment withdrawal and may be due to microvasculitis.
INTRODUCTION:Bortezomib-induced peripheral neuropathy typically presents as a painful, length-dependent sensory predominant neuropathy. METHODS: A case report, including nerve pathology, is presented of a man with multiple myeloma who developed a severe motor predominant polyradiculoneuropathy in the setting of bortezomib treatment. We also review the Mayo Clinic Hematology Dysproteinemia database for patients treated with bortezomib. RESULTS: A 53-year-old man with Stage III multiple myeloma developed a severe motor predominant polyradiculoneuropathy following bortezomib treatment with electrophysiological features of multiple conduction blocks and pathological evidence of peripheral nerve microvasculitis. Our institutional experience is that 36.5% of dysproteinemia patients treated with bortezomib develop treatment-emergent peripheral neuropathy, and the most common pattern is a painful sensory predominant peripheral neuropathy. CONCLUSIONS: A motor predominant polyradiculoneuropathy is a rare presentation of bortezomib-associated peripheral neuropathy in multiple myelomapatients which may progress despite treatment withdrawal and may be due to microvasculitis.
Authors: Nathan P Staff; Jewel L Podratz; Lukas Grassner; Miranda Bader; Justin Paz; Andrew M Knight; Charles L Loprinzi; Eugenia Trushina; Anthony J Windebank Journal: Neurotoxicology Date: 2013-09-12 Impact factor: 4.294
Authors: Shan Lu; Kelsey Gasior; Haiyang Yu; Digvijay Singh; Sonia Vazquez-Sanchez; Olga Tapia; Divek Toprani; Melinda S Beccari; John R Yates; Sandrine Da Cruz; Jay M Newby; Miguel Lafarga; Amy S Gladfelter; Elizabeth Villa; Don W Cleveland Journal: Science Date: 2020-12-17 Impact factor: 47.728